← Back to screener

PALISADE BIO, INC. PALI

Rank #2423 · Nasdaq · $0.2B market cap
⚠ Going-concern flag — the auditor (Baker Tilly US, LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
19.5
P/E
-13.9
P/B
17.80
ROE
-127.6%
Op. Margin
–%
Debt Ratio
30%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -13.9x, P/B 17.80x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -127.6%. Ranks in the top 95% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 30%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 100.0% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$-0.0B-1427.1-107
2012$0.0B$-0.0B$-0.0B$0.0B-3325.631
2013$0.0B$-0.0B$-0.0B$0.0B-3325.623
2014$0.0B$-0.0B$-0.0B$0.0B-2491.1662
2015$0.0B$-0.0B$-0.0B$0.0B-11385.4174
2016$0.0B$-0.0B$-0.0B$0.0B-183896.856
2017$0.0B$-0.0B$-0.0B$0.0B-127027.2227
2018$0.0B$-0.0B$-0.0B$0.0B-5118.147
2019$0.0B$-0.0B$-0.0B$0.0B-3176.719
2020$0.0B$-0.0B$-0.0B$0.0B-56071.824
2021–$-0.0B$-0.0B$-0.0B–-121
2022–$-0.0B$-0.0B$-0.0B–-31
2023$0.0B$-0.0B$-0.0B$0.0B–45
2024$0.0B$-0.0B$-0.0B$0.0B-5228.022
2025$0.0B$-0.0B$-0.0B$0.0B–30

← See the full screener